Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Northbrook, Illinois Clinical Trials

A listing of Northbrook, Illinois clinical trials actively recruiting patient volunteers.

RESULTS

Found (72) clinical trials

Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis

This is an open-label single-arm trial to evaluate the efficacy of Rifaximin in patients with active microscopic colitis (MC). 10 subjects will be asked to take 500mg Rifaximin three times per day for 4 weeks. The primary endpoints will be histologic response and clinical remission (less than 3 stools per ...

Phase

9.21 miles

Learn More »

Azithromycin Treatment for the Airway Microbiome in Asthma

The purpose of this study to determine whether the bacteria inside the lungs of people with asthma can be modified (changed) if they are given an antibiotic and if this change is associated with an improvement in asthma symptoms.

Phase

9.21 miles

Learn More »

Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)

Approximately 50% of heart failure patients exhibit preserved left ventricular (LV) ejection fraction (EF), and therefore have HF with preserved EF (HFpEF). There are currently no proven effective pharmacologic interventions. Exercise intolerance with reduced aerobic capacity is the hallmark of HFpEF and greatly impairs quality of life (QOL). During exercise, ...

Phase

9.5 miles

Learn More »

A Six Week Efficacy Safety and Tolerability Study of V565 in Crohn's Disease

This study will be a multiple-site, double-blind, placebo-controlled, parallel-group study in approximately 126 subjects with a confirmed diagnosis of CD for at least three months and have CD involving the ileum and/or colon. Following a screening period of up to 28 days, subjects will be randomly allocated into one of ...

Phase

9.5 miles

Learn More »

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

RGN-137 will be evaluated for efficacy and safety compared to a Placebo. A matched-pair design will be used to evaluate RGN-137 treatment versus placebo for treatment of 15 subjects with JEB or DEB. Eligible subject must have 1 set of matched-pair wound. The investigator will assign pair of index wounds, ...

Phase

9.5 miles

Learn More »

A Randomized Phase 2 Study of Cemiplimab ISA101b in HPV16-Positive OPC

This study will assess the ability of ISA101b to improve Overall Response Rate in subjects with platinum refractory (progression on or within 6 months of platinum therapy) HPV16 positive OPC, when combined with cemiplimab, an investigational anti-PD-1 antibody being developed by Regeneron Pharmaceuticals. ISA101b is a therapeutic cancer vaccine that ...

Phase

9.5 miles

Learn More »

Communication Intervention for Toddlers With Hearing Loss

While children with hearing loss (HL) are experiencing greater gains in spoken language than ever before, considerable variability exists and many children with HL continue to have poorer language skills than their hearing peers. Critical to reducing this variability is the identification of: (a) effective early communication interventions for children ...

Phase

9.5 miles

Learn More »

Maximizing Outcomes for Preschoolers With Developmental Language Disorders

A multi-site, phase 2, randomized clinical trial will be used to determine whether communication support strategies are effective for improving language outcomes in children with emergent developmental language disorder. At study entry, 108 children with emergent developmental language disorder (DLD) at 30 months of age will be randomly assigned 1:1 ...

Phase

9.5 miles

Learn More »

A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis (AD).

Phase

9.56 miles

Learn More »

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

This is a parallel group, double blind, vehicle-controlled study in which ARQ-154 foam or vehicle is applied once daily x 8 weeks to subjects with seborrheic dermatitis.

Phase

9.56 miles

Learn More »